Skip to main content
OpenTrials

Clinical trial condition

Recurrent Adrenal Cortical Carcinoma

Explore clinical trials studying Recurrent Adrenal Cortical Carcinoma. Study availability and eligibility vary by location and protocol.

2 public trials 1 recruiting study
Refine in advanced search Browse all conditions

Recurrent Adrenal Cortical Carcinoma trial results

Recruiting

Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer

NCT06900595

Conditions
Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +16 more
Locations
  • UC San Diego Moores Cancer Center La Jolla, California, United States
  • Valley Children's Hospital Madera, California, United States
  • UCHealth University of Colorado Hospital Aurora, Colorado, United States
  • Lurie Children's Hospital-Chicago Chicago, Illinois, United States
View all 77 locations
View Trial Details
Active, Not Recruiting

Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors

NCT02867592

Conditions
Adenocarcinoma, Adrenal Cortex Diseases, Adrenal Cortex Neoplasms, +92 more
Locations
  • Children's Hospital of Alabama Birmingham, Alabama, United States
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Arkansas Children's Hospital Little Rock, Arkansas, United States
  • Kaiser Permanente-Anaheim Anaheim, California, United States
View all 142 locations
View Trial Details

Related conditions